2.

Basics in surgery 3.stupor 14.

Wound
Hernia 4.crisis 17 mg/dL A. (Zinc)
Thyroid B. (Copper)
Breast 5. C. (Stibium)
D. (Chromium)
A. 1.3.4. B. 3.4.5. C. 1.2.5. D. 1.2.4
15.
1. 8. Chvosteks Trousseaus sign A.
A. B.
B.(ICW)(ECW) A. hyponatremia C.
C.(ECW) B. hypokalemia D.
D.(multifrequencybioelectric impedance) C. hypocalcemia
D. hypomagnesemia 16.
E. Inulin (ECW)
9. Hypomagnesemia
2. A. A.
A. B. B. K
B. C. C.
C. D. D.
D.
10. 50 17.
3. 129 mEq/L A.
A. 72 mEq/LpH 7.60PCO250 torr B.
B. C.
C. A. D.
D. (hypovolemia) B.
C. 18.
D. A. branched chain amino acids
4. (hypokalemia) B. >35 Kcal/kg/day
A. 11. C. MCT fat
B. A. HCl D. cyclic TPN
C. B. NaCl
D. C. KCl 19.
D. NaHCO3
5. hypokalemia A. Arginine
A. 12. B. Glutamine
B. 1. C.Branched chain amino acids
C. 2. D.
D. 3. 3
4. 20.
6. 5. A. Branched chain amino acids
A. spironolactone A. 1.2.3.4 B. 1.4.5 C. 1.5 D. 1.4 B. Essential amino acids
B. -blocker C. Arginine
C. cyclosporine 13. D. Glutamine
D. cortisol A. enterocutaneous fistula
B. short bowel syndrome 21.
7. Ca++ C. anorexia nervosa 1.(branched chain amino acids)
1. 2.2 2.7 mg/dL 9 11 mmol/L D. acute burn 2.(catabolic)(urea)
 C. (atelectasis) A. (nitrogen monoxide)
3.(purine) D. (pneumonia) B. (carbon dioxide)
(pyrimidines) C. (oxygen)
4.(insulin) 29. 72 D. (helium)
5.(aromatic) LeucineIsoleucine Valine A. atelectasis
B. 37. CO2
A. 1.2.3. B.1.2.4. C.2.3.4. D 2.3.5. 91 1 C.
D. leaking anastomosis A.
22. (albumin) B.
A. 30. C.
B. A. D.
C. B.
D. (nephrotic syndrome) C. 38. CO2
D. A. 20 mmHg
23. B.
31. C.
A. Albumin A. 1 D. CO2
B. Transferrin B.
C. Prealbumin C. 39.
D. Globulin D. 48 A. NO
B. helium
24. RQ 0.7 32. C. neon
A. obesity D. argon
a. B. 3
b. C. chronic obstructive pulmonary disease 40. pneumoperitoneum
c. D. physiological effects potential clinical outcome
d.
33. hypothermia A. intracranial pressure central perfusion pressure
25.
A. glucocorticoids A. fibrinolytic activity B. renal blood flow urine output
B. thyroid hormone B. C. sympathetic response ileus
C. insulin C. D. CVPcentral venous pressure CWPcapillary
D. IGF-1 D. wedge pressure cardiac work

26. 34. pneumoperitoneum 41. gas embolism

A. immunoglobulins A. liver resection
B. delayed cutaneous hypersensitivity A. B. gastric resection
C. antibodies B. 25 mmHg C. colon resection
D. complements C. D. spleen resection
D. nitrous oxide
27. 42. (fresh frozen plasma)
A.
A. 35. B.
B. A. C.
C. B. D.
D. C. (carpal tunnel release)
D. 43. citrated blood product

28. 24
A. (wound infection) 36. (laparoscopic surgery) (artificial A. (Potassium)
B. (bacteremia) pneumoperitoneum) B. (Magnesium)
C. (Calcium) C. PSAprostate specific antigen A.
D. (Chloride) D. CA15-3 B. (steroid)
C.
44. 51. D.

A. A. Meperidine 59.
B. B. Morphine A.
C. C. Ketoprofen B.
D. D. Acetaminophen C.
D. (tension)
45. 52. HIV
A. (biliary tract disease) A. blood 60.
B. (appendicitis) B. vaginal secretion A.
C. (peptic ulcer) C. breast milk B.
D. (colon perforation) D. air C.
D.
46. splenectomyabsolute indication 53. blind loop syndrome
61.
A. Hereditary spherocytosis A. constipation A.
B. idiopathic thrombocytopenia purpura B. abdominal pain B.
C. thalassemia major traumatic C. weight loss C.
D. splenic rupture D. megaloblastic anemia D.

47. purpura 54. gynecomastia 62.

epistaxisgingival bleeding A.
thrombocytopenia A. testicular tumor D.
B. C.
A. systemic lupus erythematosus C. cimetidine, cannabis D.
B. idiopathic thrombocytopenic purpura D. heavy smoker
C. congenital thrombocytopenia
D. hypersplenism 55. 63.
A. (contraction) A.
48. B. myofibroblast B.
C. (contracture) C.
A. open splenectomy D. D.
B. laparoscopic splenectomy
C. ligation of splenic artery 56. 64.
D. balloon occlusion of splenic artery A. A.
B. B.
49. (overwhelming postsplenectomy C. (macrophages) C.
infection) D. (fibroblasts) D.
A. (Haemophilus influenza)
B. (Streptococcus pneumoniae) 57. 65.
C. (Neisseria meningitides) A. A A.
D. (Salmonella species) B. C B.
C. C.
50. tumor biomarker D. D.

A. CA19-9
B. carcinoidCEA 58. 66.
A. 73.
B. A. Clostridium species 81. systemic inflammatory
C. B. Proteus response syndrome
D. C. Morganella A.
D. Bacteroides fragilis B. tachycardia
67. C. tachypnea
A. 30~60 D.
B. 74. fungus infection
A. Aspergillus 82. sepsis
C. 2~3 B. Candida albicans A.
D. 24 C. Yeast B.
D. Blastomyces C.
68. D.
A. 2 3 75. (aerobes)
A. Ciprofloxacin 83.
B. B. Ceftriaxone
C. Gentamycin A. Anti-TNF-
C. mg D. Metronidazole B. Activated protein C
C. IL-1 receptor inhibitor
D. 76. D. Platelet-activating factor
A. Dexon
69. incarcerationherniorrhaphy B. PDS 84. cytokine proinflammatory cytokine
surgical wound C. coated Vicryl A. TNF-
A. clean D. Prolene B. IL-1
B. clean contaminated C. IL-8
C. contaminated 77. (absorbable suture) D. IL-10
D. dirty contaminated A. silk
B. polyproylene (prolene) 85.
C. nylon A. Tumor necrosis factor
70. dirty and infected wounds D. chromic catgut B. Nitric oxide
A. C. Angiogenin
B. 78. D. Myocardial depressant substance
C. A. Catgut
D. B. Coated vicryl 86. (Pneumoperitoneum
C. Dexon
71. 62 adhesion ileus D. PDS A.
0.5 B. X X Chest PA
79. pulmonary artery catheterization
A. dirty-infected wound C.
B. A. D.
C. 30 cephalosporin B.
D. C. Thrombophlebitis 87.
D. Left bundle-branch block A.
B. Nosocomial pneumonia Gram
72. (nosocomial infection) 80. ARDSAcute respiratory distress syndrome positive
A. C. Gram negative
B. A. X D.
C. B. PaO2/FiO2200
D. C.PAWPPulmonary artery wedge pressure18 mmHg 88.
D.Acute onset A. volume-cycled ventilation
B. pressure-cycled ventilation 96. 103. FNAC
C. pressure support ventilation HyperparathyroidismPheochromocytoma
D. controlled mandatory ventilation A. A. 1%
B. B. 5%
89. (tetanus) C. C. 15%
A. (hyperbaric oxygen) D. D. 30%
B.
C.
D. (tracheostomy) 97. (anaplastic cancer) 104.
A. 40 A. follicular carcinoma
90. (hernia) B. B. de Quervain
A. C. C. Graves thyrotoxicosis
B. D.
C. D. Plummer
D. 98. 45
105.
91. A. A. TSH
A. (papillary thyroid carcinoma) B. (thyroglobulin) B. TSH
B. (follicular thyroid carcinoma) C. T4
C. (medullary thyroid carcinoma) D. C. T4 T3 20%
D. (anaplastic thyroid carcinoma)
99. D. T3T4
92.
A. (papillary thyroid carcinoma) A. 106.
B. (follicular thyroid carcinoma) B. A.
C. (medullary thyroid carcinoma) C. B. TSH T4
D. (anaplastic thyroid carcinoma) D. C. Hashimoto thyroiditis TSH T4
D.
93.
A. papillary carcinoma 100. 107. Graves disease
A.
B. follicular carcinoma 10 A. B.
C. medullary carcinoma B. C.
C. D.
D. MEN D.
108. (thyrotoxicosis)
94. Follicular carcinoma 101. 40 A.
B.
A. 50 A. C.
B. B. 5 D. Propranolol
C. C.
D. D. 109. Thyroid storm

95. medullary cancer 102. fine needle aspiration a. 35
b.
A. C calcitonin A. c. 140/min
B. follicular d.
B. MEN adenomafollicular carcinoma
C. 10~20 C. 110. (thyroid storm, thyroid crisis)
D. I-131 D.
A. A. 124. BRCA1 BRCA2
B. 38.5 B. A. BRCA1 17 BRCA2 13
C. C. B. BRCA1 1 BRCA2 2
D. D. 90% C. BRCA1 13 BRCA2 17
D. BRCA1 2 BRCA2 1
118. insulinoma
111. A. 125.
B. Whipples triad A. ductal ectasia
A. C. insulinU/ml-glucosemg/dL1 B. sclerosing adenosis
B. D. glucagon test insulinoma C. atypical hyperplasia
C. D. carcinoma in situ
D. 119. Adrenogenital syndrome
A. C21 hydroxylation defect 126.
112. B. C11 hydroxylation defect Invasive breast cancer
A. C. ACTH A. Lobular carcinoma in situ
B. bronchial pouch D. 17-ketosteroids B. Apocrine change
C. Papilloma
C. Congenital adrenal hyperplasia D. Atypical ductal hyperplasia
21-hydroxylase deficiency
D. steroid cortisol, aldosterone androgen 127.
Decreased aldosterone and cortisol in blood A.
113. Elevated urinary 17-ketosteroids B. (craniocaudal)
A. (mediolateral oblique)
B. 120. C.
C. A. D.
D. B.
C. 128. TNM
114. D. (atypical hyperplasia) A.
A. B.
B. (radioisotopic subtraction scan) 121. C.
C. A. D.
D. B.
C. 129. 50 2
115. (recurrent laryngeal nerve) D. 2

A. 122. TNM
A. A.
B. B. B.
C. C.
C. D. D.
D.
123. 130. (noninvasive breast cancer)
116. MEN A. fat intake A. (medullary carcinoma)
A. B. (tubular carcinoma)
B. B.lactation C. (lobular carcinoma)
C. C.multiparous D. (intraductal carcinoma)
D.
D. 5 131.
117. (multiple endocrine neoplasia A. (infiltrating ductal carcinoma)
type I) B. (invasive lobular carcinoma)
C. (ductal carcinoma in situ) C. Intercostal nerve
D. (lobular carcinoma in situ) D. 50% D. Radial nerve

132. 146. (breast conservative therapy)
A. Pagets disease 139.
B. Mucinous carcinoma A. 20-30% A.
C. Inflammatory carcinoma B. bone, lung, liver B.
D. Papillary carcinoma C. Tamoxifen C.
D. 5 25-35% D.
133. , comedo type
140. 147.
A. Comedo type A. A.
B. B. B.
C. C. C.
D. D. SLE
D. Rotters nodes
134. 30 X 4.5 148.
microcalcification 141. level I nodes
DCISComedo type A. external mammary group A.
A. B. axillary vein group B.
B. C. central group C.
C. D. scapular group D. Disease free
D.
142. level 149.
135. level A.
A. DCIS (ductal carcinoma in situ) comedo type A. thoracodorsal artery B.
B. DCIS (ductal carcinoma in situ) B. C.
C. apical node D.
C. LCIS (lobar carcinoma in situ) D. pectoralis minor muscle
150. breast conserving surgery
D. LCIS (lobar carcinoma in situ) 143. modified radical mastectomy
A.
136. DCISLCIS A. long thoracic nerve thoracodorsal nerve B.
B. thoracodorsal nerve winged scapula
A. DCIS C.
B. DCIS C.
C. DCIS D. D. 4
D. LCIS DCIS
151. breast conserving therapy
137. (ductal carcinoma in situ) 144. (MRM) MRM
A.
A. A. (level) B.
B. B. 10
C. C. C.
D. (non-comedo) D. D.

138. 145. Radical mastectomyWinged 152. 2 open biopsy

A. scapula
B. TNM T3 A. Long thoracic nerve Lumpectomy
C. B. Thoracodorsal nerve
A. Lumpectomy 159. 165. 70 2 MRM
B. Lumpectomy A. Antiestrogen ER (+), PR(+)
C. Radical mastectomy B. Aromatase inhibitors
D. Modified radical mastectomy C. Specific estrogen receptor modulator A.
D. Her-2/neu receptor protein antibody B. Tamoxifen
153. (post-mastectomy breast reconstruction) C.
160. 70 D.
A. (rectus abdominis myocutaneous flap)
B. (latissimus dorsi myocutaneous flap) 1.5 166.
C. (implant) (saline-filled silicone bag)
D. Tamoxifen A. long thoracic nerve
B. thoracodorsal nerve
154. (breast reconstruction) A. Tamoxifen C. intercostal brachial nerve
A. (immediate)(delayed) B. Tamoxifen D.
(psychological disturbance) C. Tamoxifen
B. (implant)(tissue D. Tamoxifen 167.
expander)
C. (TRAM) 161. Tamoxifen A.
(implant) A. B. ER+
D. (latissimus dorsi myocutaneous flap) B. ER-negative C. ER
(implant) C. D. ER+ ER
D. Tamoxifen LDL
155. Postmastectomy breast
reconstruction 168. Adjuvant therapy
A. 162. (adjuvant systemic therapy)
B. A.
C. A. B.
D. B. Tamoxifen C.
D.
C.
156. Sentinel LN D.
A. largest LN 169.
B. first LN 163. A. CMF
C. highest level of LN A. cyclophosphamide, methotrexate, 5-FU
FAC5-FU, anthracycline,
D. most accurate LN cyclophosphamide ACanthracycline, cyclophosphamide
B. 10
157. sentinel B. CMF disease-free interval
lymph node biopsy complete C.
axillary dissection C. disease-free interval CMF
A. 2 D. breast conservative therapy D. Anthracycline-base
B. disease-free interval
C. Taxane
D. 164. Taxane
A. 170.
158. A.
A. B. Apoptosis B.
B. C. (antiangiogenesis) C. estrogen receptor
C. D. Estrogen level D.
D.
171.
A. BRCA1 BRCA2 combined oval lesion
B. 1 A. oval lesion benign lesion
C. B. oval lesion malignant lesion
D. C. galactocele
D. aspiration
172. Phyllodes tumor A.
A. B.(excision biopsy) 185. 35 bloody
B. C. nipple discharge
D.
C. A. cystosarcoma phylloides
D. non-epithelial tumor 179. 22 B. fibrocystic disease
C. intraductal papilloma
A. D. fibroadenoma
173. (phyllodes tumor) B.
C. 186. 65 bloody discharge

A. D.
B. A. ultrasound
C. B. discharge cytology
D. 180. 30 32 1.0 C. ductography
D. serum prolactin
A.
174. 32 1 B. 187. 35
phyllodes C.
tumor D. A. fibroadenoma
A. modified radical mastectomy B. fibrocystic disease
181. 25 2.2 C. medullary carcinoma
B. D. intraductal papilloma
C. 1
D. A. 188. 45 3
B. infiltrating duct carcinoma
175. Pagets disease C. X TNM
A. D.
B. A. stage
C. 182. B. stage
D. C. stage
A. D.stage
176. Pagets disease B.
A . C. 189. modified radical mastectomyMRM
B. D. 2/20
C. ER(-), PR(-), Her-2/neu
D. 183. 25 movable
A. Tamoxifen
177. B.
A. A. breast cancer C.
B. B. breast abscess D.
C. C. fibroadenoma
D. D. intraductal papilloma
190. 67 3
178. 28 184. 40 1
mammography 33 radiolucent and radiopaque
 1.5 197. 49 4
graft tenderness Creatinine level 3.1
mg/dL renal papilla edema

A. A. Angiogram
B. B. Cyclosporine
C. C.
D. D. Nuclear scan renal biopsy
immunoglobulin therapy
191.
Modified radical mastectomy 198.

A. Rotters node A. hepatitis B virus
B. ILevel I B. hepatitis C virus
C. IILevel II C. herpes simplex virus
D. Internal mammary chain D. cytomegalovirus

192. 199.
A. 90% A.
B. 1/4 B.
C. 1/4-1/5 C. Epstein-Barr
D. D.

193. T
A. T (antigen-presenting cell)
(MHC)
B. T (alloantigen)
C. CD 28 3 (LFA-3)
D. 1 (LFA-1) 1 (ICAM-1)

194. preformed antibody

A. hyperacute rejection
B. acute rejection
C. chronic rejection
D. acute tubular necrosis of kidney

195. cadaveric donor

A. DIC
B. diabetes insipidus
C.
D.

196.
A.
B.
C.
D.